{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:19:09Z","timestamp":1782271149796,"version":"3.54.5"},"reference-count":86,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have been taking cancer research by storm as they provide valuable therapeutic benefits to cancer patients in terms of immunotherapy. Melanoma and non-small cell lung cancer (NSCLC) are among the most prevalent cancer varieties that were utilized in ICI trials with many other cancer types being involved too. Despite impressive clinical benefits of overall response rate (ORR), progression-free survival (PFS), etc., ICIs are also accompanied by various immune-related adverse events (irAEs). Amongst the irAEs, cardiotoxicity bags a crucial role. It is of paramount importance that ICI-induced cardiotoxicity should be studied in detail due to its high mortality rate although the prevalence rate is low. Patients with ICI cardiotoxicity can have a greatly enhanced life quality despite adverse reactions from ICI therapy if diagnosed early and treated in time. As such, this review serves to provide a complete insight into the predisposing factors, mechanism, diagnostic methods and treatment plans revolving around ICI-induced cardiotoxicity.<\/jats:p>","DOI":"10.3389\/fcvm.2022.997660","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T07:07:55Z","timestamp":1663657675000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment"],"prefix":"10.3389","volume":"9","author":[{"given":"Sridha","family":"Ganesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e000247","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO Open."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on fears","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","article-title":"Pembrolizumab and atezolizumab in triple-negative breast cancer","volume":"70","author":"Kwapisz","year":"2021","journal-title":"Cancer Immunol Immunother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"100420","DOI":"10.1016\/j.ijcha.2019.100420","article-title":"Cardiotoxicity from immune checkpoint inhibitors","volume":"25","author":"Michel","year":"2019","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"5-year survival with combined Nivolumab and Opilimumab in advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune checkpoint inhibitors and cardiotoxicity: an analysis of spontaneous reports in eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0124059","DOI":"10.1371\/journal.pone.0124059","article-title":"Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153","volume":"10","author":"Baban","year":"2015","journal-title":"PLoS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S4400","DOI":"10.21037\/jtd.2018.12.78","article-title":"Cardio-toxicity of checkpoint inhibitors","volume":"10","author":"Muller","year":"2018","journal-title":"J Thorac Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-020-01002-w","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: clinical risk factors","volume":"23","author":"Pirozzi","year":"2021","journal-title":"Curr Oncol Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"794842","DOI":"10.1155\/2015\/794842","article-title":"Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science."},{"key":"B20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"726426","DOI":"10.3389\/fcvm.2021.726426","article-title":"Immune checkpoint inhibitors and the heart","volume":"8","author":"Mocan-Hognogi","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"publisher","first-page":"7195","DOI":"10.3390\/ijms21197195","article-title":"Immune checkpoint inhibitors and cardiac toxicity in patients treated for non-small lung cancer: a review","volume":"21","author":"Slawinski","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur Heart J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","article-title":"Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis","volume":"70","author":"Grani","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/CIRCRESAHA.109.199802","article-title":"Myeloid differentiation factor-88\/interleukin-1 signaling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy","volume":"105","author":"Blyszczuk","year":"2009","journal-title":"Circ Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.34172\/jcvtr.2020.07","article-title":"Oxidized cholesterol exacerbates toll-like receptor 4 expression and activity in the hearts of rats with myocardial infarction","volume":"12","author":"Khorrami","year":"2020","journal-title":"J Cardiovasc Thorac Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"H2024","DOI":"10.1152\/ajpheart.01188.2009","article-title":"Myeloid differentiation factor-88 contributes to TLR9-mediated modulation of acute coxsackievirus B3-induced myocarditis in vivo","volume":"298","author":"Riad","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccas.2019.11.080","article-title":"Myocardial and pericardial toxicity associated with immune checkpoint inhibitors in cancer patients","volume":"2","author":"Chahine","year":"2020","journal-title":"JACC Case Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/imt-2019-0003","article-title":"Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report","volume":"11","author":"Asai","year":"2019","journal-title":"Immunotherapy."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1056\/NEJMcp1404070","article-title":"Clinical practice. Acute pericarditis","volume":"371","author":"LeWinter","year":"2014","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jtho.2019.02.026","article-title":"Immune checkpoint inhibitor-associated pericarditis","volume":"14","author":"Altan","year":"2019","journal-title":"J Thorac Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","article-title":"Pericardial effusion under nivolumab: case-reports and review of the literature","volume":"7","author":"Saade","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","article-title":"Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports","volume":"70","author":"Inno","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5218","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"13","author":"Shalata","year":"2021","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e012219","DOI":"10.1161\/JAHA.119.012219","article-title":"Novel insights into the NLRP 3 inflammasome in atherosclerosis","volume":"8","author":"Jin","year":"2019","journal-title":"J Am Heart Assoc."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040179","article-title":"Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models","author":"Quagliariello","year":"2020","journal-title":"J Pers Med 10."},{"key":"B44","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1634\/theoncologist.2018-0157","article-title":"Checkpoint inhibitor safety working, myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action","volume":"23","author":"Neilan","year":"2018","journal-title":"Oncologist."},{"key":"B45","doi-asserted-by":"publisher","first-page":"105913","DOI":"10.1016\/j.cct.2019.105913","article-title":"Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): Rational, design, and baseline characteristics for the main trial","volume":"89","author":"Zhang","year":"2020","journal-title":"Contemp Clin Trials."},{"key":"B46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck","year":"2019","journal-title":"Int J Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ijcard.2019.03.042","article-title":"How cardio-oncology is called to prove its maturity","volume":"288","author":"Tini","year":"2019","journal-title":"Int J Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.esmoop.2021.100216","article-title":"Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy","volume":"6","author":"Delombaerde","year":"2021","journal-title":"ESMO Open."},{"key":"B49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/1759-7714.13250","article-title":"Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity","volume":"11","author":"Guo","year":"2020","journal-title":"Thorac Cancer."},{"key":"B50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000498985","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature","volume":"12","author":"Agrawal","year":"2019","journal-title":"Case Rep Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/ejhf.806","article-title":"Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia","volume":"19","author":"Berg","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B55","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/biom11060785","article-title":"An emergent form of cardiotoxicity: acute myocarditis induced by immune checkpoint inhibitors","volume":"11","author":"Esposito","year":"2021","journal-title":"Biomolecules."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European association of cardiovascular imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2013.02.061","article-title":"Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction","volume":"61","author":"Ersboll","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/ehjci\/jex308","article-title":"Additional diagnostic value of CMR to the European Society of Cardiology (ESC) position statement criteria in a large clinical population of patients with suspected myocarditis","volume":"19","author":"Biesbroek","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.3389\/fphar.2019.01350","article-title":"Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Pharmacol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11886-017-0835-0","article-title":"Cardiovascular toxicities associated with cancer immunotherapies","volume":"19","author":"Wang","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for immunotherapy of cancer toxicity management working, managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"National comprehensive cancer, management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fphar.2020.00972","article-title":"How to monitor cardiac complications of immune checkpoint inhibitor therapy","volume":"11","author":"Spallarossa","year":"2020","journal-title":"Front Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018"},{"key":"B71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40959-021-00114-x","article-title":"Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases","volume":"7","author":"Matzen","year":"2021","journal-title":"Cardio-oncology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"6797","DOI":"10.26355\/eurrev_202111_27124","article-title":"Interleukin-1 blocking agents as promising strategy for prevention of anticancer drug-induced cardiotoxicities: possible implications in cancer patients with COVID-19","volume":"25","author":"Quagliariello","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/antiox9121182","article-title":"Multiple effects of ascorbic acid against chronic diseases: updated evidence from preclinical and clinical studies","volume":"9","author":"Berretta","year":"2020","journal-title":"Antioxidants."},{"key":"B78","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/1735-1995.193510","article-title":"Effect of long-term Vitamin C intake on vascular endothelial function in diabetic children and adolescents: a pilot study","volume":"21","author":"Sabri","year":"2016","journal-title":"J Res Med Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1111\/cas.15136","article-title":"Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy","volume":"112","author":"MaruYama","year":"2021","journal-title":"Cancer Sci"},{"key":"B80","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ijpharm.2015.08.039","article-title":"Submicron complex lipid carriers for curcumin delivery to intestinal epithelial cells: effect of different emulsifiers on bioaccessibility and cell uptake","volume":"494","author":"Yucel","year":"2015","journal-title":"Int J Pharm"},{"key":"B81","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40959-021-00112-z","article-title":"Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review","volume":"7","author":"Kazama","year":"2021","journal-title":"Cardiooncology."},{"key":"B82","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1536\/ihj.21-653","article-title":"Asymptomatic myocarditis with mild cardiac marker elevation following nivolumab-induced myositis","volume":"63","author":"Shindo","year":"2022","journal-title":"Int Heart J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biochi.2020.09.018","article-title":"The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2","volume":"179","author":"Muralidar","year":"2020","journal-title":"Biochimie"},{"key":"B84","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s12265-020-10013-8","article-title":"COVID-19, immuno-oncology and cardiovascular disease: viewpoint from the intersection","volume":"13","author":"Siddiqi","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/iid3.484","article-title":"The prognostic value of myocardial injury in COVID-19 patients and associated characteristics","volume":"9","author":"He","year":"2021","journal-title":"Immun Inflamm Dis."},{"key":"B86","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.997660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T07:07:58Z","timestamp":1663657678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.997660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":86,"alternative-id":["10.3389\/fcvm.2022.997660"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.997660","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"article-number":"997660"}}